In April, McDermott was pleased to once again host our annual European Health & Life Sciences Symposium in Paris. Welcoming a crowd of more than 300 innovators, investors, business leaders and advisers from across the...more
5/13/2025
/ Acquisitions ,
Biotechnology ,
EU ,
Financing ,
Investment ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Venture Capital
In April 2025, we were proud to host the annual European Health & Life Sciences Symposium at the Shangri-La hotel in Paris. Attended by some 300 delegates from across the industry, participants including investors,...more
5/5/2025
/ Artificial Intelligence ,
Biologics ,
Biotechnology ,
Clinical Trials ,
Healthcare ,
Healthcare Reform ,
Innovative Technology ,
Investment ,
Investors ,
Life Sciences ,
Pharmaceutical Industry ,
Regulatory Requirements ,
Technology Sector ,
Venture Capital
Welcome to this edition of Credit Conditions, a quarterly publication from McDermott Will & Emery that analyzes recent debt market trends.
The fourth quarter of 2024 marked a pivotal moment in the debt market, as the...more
3/3/2025
/ Acquisitions ,
Capital Markets ,
Capital Raising ,
Federal Reserve ,
Financial Markets ,
Financial Services Industry ,
Interest Rates ,
Investment ,
Investment Funds ,
Mergers ,
Private Equity
The Private Markets Update highlights key developments emerging from private markets across Europe, the UK and the United States, exploring the cross-border issues that matter to investors and sponsors in alternative assets. ...more
10/16/2024
/ Acquisitions ,
Artificial Intelligence ,
Capital Markets ,
Cross-Border ,
EU ,
EUMR ,
Financial Conduct Authority (FCA) ,
Greenwashing ,
Healthcare ,
Investment ,
Investment Management ,
Investors ,
Life Sciences ,
Mergers ,
Private Equity ,
Regulatory Agenda ,
Regulatory Requirements ,
UK ,
United States
Meanwhile, cash-strapped biotechs have in many cases been forced to leverage relationships with big pharma to address liquidity. Cash is king in a financing environment such as we have observed over the last 18 months, and...more
12/22/2023
/ Borrowers ,
Capital Markets ,
EBITDA ,
Environmental Social & Governance (ESG) ,
EU ,
Financing ,
Healthcare ,
Investment ,
Lenders ,
Life Sciences ,
Secondary Credit Markets ,
Technology Sector ,
Venture Capital
200+ leading individuals in healthcare, life sciences and private equity gathered at the Shangri-La Hotel in Paris for the European Health & Life Sciences Symposium 2023 to enjoy a day packed with fireside chats, in-depth...more
11/28/2023
/ Artificial Intelligence ,
Capital Markets ,
Digital Health ,
EU ,
Healthcare ,
Information Technology ,
Investment ,
Investors ,
Life Sciences ,
Pharmaceutical Industry ,
Private Equity ,
Technology ,
UK
240+ leading individuals in healthcare, life sciences and private equity gathered at The Langham Hotel in central London for HPE Europe 2023 for a day packed with fireside chats, in-depth plenary sessions and an abundance of...more
Welcome to the inaugural Private Markets Update, which highlights developments in the European private markets, covering the issues that matter to investors in alternative assets. Touching on themes as diverse as predictions...more
5/31/2023
/ Acquisitions ,
Capital Markets ,
Cross-Border ,
EU ,
FinTech ,
Germany ,
Investment ,
Investors ,
Mergers ,
National Security ,
OECD ,
Pillar 2 ,
Private Equity ,
Private Equity Funds ,
Restructuring ,
UK
Key Trends & Opportunities in Life Sciences and Healthcare Investing -
The current macroeconomic environment is creating challenges for healthcare and life sciences businesses, which have been impacted hard by wage...more
12/9/2022
/ Capital Markets ,
Digital Health ,
EU ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Pharmaceutical Industry ,
Private Equity ,
Technology ,
UK
After an insightful conference in Cannes, our partners have compiled some of the key takeaways from IPEM 2022.
As well as exploring the private equity landscape in the UK, Germany, France and Italy, we also explore the...more
10/25/2022
/ Acquisitions ,
Debt ,
Economic Growth ,
Environmental Social & Governance (ESG) ,
EU ,
France ,
Funding ,
Germany ,
Healthcare ,
Investment ,
Investors ,
Italy ,
Mergers ,
Private Equity ,
Publicly-Traded Companies ,
Small and Medium-Sized Enterprises (SMEs) ,
UK ,
Venture Capital
During this session, Aymen Mahmoud, partner and co-head of the London Finance, Restructuring and Special Situations Group, led a discussion that explored the metrics that can be used to differentiate between short- and...more
On 5 March 2021, the Financial Conduct Authority (FCA) set out certain key dates for the cessation of all 35 London Inter-Bank Offered Rate (LIBOR) settings published by ICE Benchmark Administration. Whilst there has been...more